Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
Pfizer/Metsera is testing MET-097i at both once-weekly and one-monthly regimens in phase 2 trials
Acknowledgements This study was supported by grants from the Chang Gung Memorial Foundation (CMRPG-5D0111, CMRPG2F0171, CMRPG2F0172, CMRPG2F0173, CMRPG-2G0361, CMRPG-2H0161, CRRPG2H0162, CMRPG-2J0261, CMRPG-2K0091, CORPG2N0141, CORPG2P0231, and CORPG2P0191), the Ministry of Science and Technology, Taiwan (104-2320-B-182A-013, 106-2314-B-182A-064, 107-2314-B-182A-138, 108-2320-B-182A-009-MY3, 108-2314-B-182A-027, 108-2321-B-182-003 and 109-2321-B-182-001) and the Taiwanese Ministry of Health and Welfare (MOHW110-TDU-B-212-124005, MOHW111-TDU-B-212-134005, MOHW112-TDU-B-212-144005)
They belong to a group of drugs called GLP-1 receptor agonists
US$ 29.10
US$ 25.43
US$ 23.54
US$ 28.97
US$ 24.12
